They raised full-year guidance while gross margin missed and operating expenses ran over. The EPS beat came from an 11% tax rate.
Thesis: Beat-and-raise with real structural legs: clean room capacity opening for DRAM, power orders above two-year average, and 40% capacity headroom with zero incremental capex driving absorption. But 46% China revenue with rising exposure is an unquantifiable tail risk, and the EPS quality is compromised by a windfall tax benefit. The revenue guide going up is genuine. The earnings quality is soft. Hold until memory clean rooms actually convert to revenue or China policy breaks.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q3 revenue at $230M proving sequential acceleration, gross margin crossing 43% on volume absorption, and memory revenue inflecting as clean rooms come online in late 2026 into 2027.
Key Risk: China at 46% of revenue and rising, with two new China customers added this quarter. Export control policy can sever nearly half the revenue base by executive order. Replacement markets take years to develop.
The Tell: CEO volunteered: 'We anticipate another year of revenue growth in 2027' with no analyst asking about 2027. He ran ahead of consensus unprompted, which either means he has real visibility into customer clean room schedules or he is managing the stock through the Veeco merger close.
Friction Level: HIGH_FRICTION — Bull sees Beat-and-raise Machine with capacity for 40% growth and margin expansion ahead. Bear sees tax-aided EPS, missed GM, flat book-to-bill for three quarters, and 46% China revenue. Same numbers, opposite reads on whether the raise is structural or timing.
2026Q2 · Aug 6, 2026
3 of 5 readings agreed3 HOLD · 2 AVOIDRead the full call
Revenue Guide Up, Quality of Beat Tilted by Tax Windfall
Beat-and-raise with real structural legs: clean room capacity opening for DRAM, power orders above two-year average, and 40% capacity headroom with zero incremental capex driving absorption. But 46% China revenue with rising exposure is an unquantifiable tail risk, and the EPS quality is compromised by a windfall tax benefit. The revenue guide going up is genuine. The earnings quality is soft. Hold until memory clean rooms actually convert to revenue or China policy breaks.
CEO volunteered: 'We anticipate another year of revenue growth in 2027' with no analyst asking about 2027. He ran ahead of consensus unprompted, which either means he has real visibility into customer clean room schedules or he is managing the stock through the Veeco merger close.
Revenue and EPS both beat, full-year guide raised from flat to mid-single-digit, Q3 guided to $230M with Q4 sequential up. Three quarters of B2B near 1.0 with backlog at $452M against $920M run rate.
CEO admits 'we have not yet seen a pickup in our order rates' in general mature while characterizing revenue improvement. GM missed at 42.7% vs 43% guide, OpEx over at $60M vs $59M, EPS leaned on 11% tax rate vs 15% forecast from equity comp windfall.
CS&I strength at $83M driven by 'really high utilization rates' and customers using upgrades because they are 'floor wall constrained.' Management explicitly frames customers as 'looking to use what they have' rather than buying new tools.
China jumped to 46% of revenue from 40% quarter-over-quarter. Ion implant equipment is a category already scrutinized by US export controls. Two new China customers added this quarter deepen dependency.
CFO confirmed capacity for revenue 40% above current run rate with absorption benefit to gross margin. GM guide raised to 43% in Q3 with further improvement in Q4, no incremental capex required to serve higher volume.
Memory declined sequentially with CEO calling it 'lumpy' and pushing clean room timing to next year. NAND confirmed as 'no trend yet.' 2027 growth thesis rests on DRAM clean rooms management cannot yet size.
CEO explicitly stated implant opportunities in indium phosphide are 'relatively small.' Data center SiC called 'still a small area.' 84% of system shipments into mature node applications despite AI narrative airtime.
+65
CONFIDENT"CEO volunteered 2027 growth guidance unprompted. CFO gave specific capacity number (40% above run rate) and confirmed absorption-driven margin benefit. Direct answers throughout Q&A with no deflection on China or memory."
Specific numbers throughout: backlog, B2B, capacity headroom, geography mix, guide detail. Some evasion on memory sizing for 2027 and customer identity on the 2nm shipment.
Q3 revenue at $230M proving sequential acceleration, gross margin crossing 43% on volume absorption, and memory revenue inflecting as clean rooms come online in late 2026 into 2027.
China at 46% of revenue and rising, with two new China customers added this quarter. Export control policy can sever nearly half the revenue base by executive order. Replacement markets take years to develop.
The verdict is public. The case behind it is Pro: the forensic reading of guidance and language, the bull and bear cases, the red flags, and the play. It opens to everyone on Nov 4, 2026.